Cost-Effectiveness of Percutaneous Lymphatic Embolization for Management of Plastic Bronchitis

Abstract

Background:

Plastic bronchitis is a dreaded complication of single ventricle physiology occurring following palliation via Fontan procedure. Medical management of plastic bronchitis often fails, requiring heart transplantation. Percutaneous lymphatic embolization is an emerging treatment for plastic bronchitis.

Methods:

To determine the cost-effectiveness of competing management strategies, a modified Markov model was constructed with patients transiting through treatments—medical management, lymphatic embolization, or heart transplantation from a hospital system perspective. Health state transitions were modeled using an institutional review board–approved retrospective review of the Children’s Hospital of Pennsylvania’s plastic bronchitis cohort. Medication pricing data were obtained from the National Inpatient Sample. Differences in costs and quality-adjusted life years (QALYs) over a five-year horizon for each group were determined. The incremental cost-effectiveness ratio was then calculated.

Results:

The mean cost of lymphatic embolization from procedure performance was US$340,941, US$385,841 for heart transplantation, and US$594,520 for medical management. The mean quality-adjusted survival of lymphatic embolization yielded an additional 0.66 QALYs (P < .03) relative to heart transplantation and 1.3 (P < .0001) relative to medical management. Orthotopic heart transplantation yielded an additional 0.66 QALYs (P = .06) when comparing heart transplantation to medical management. Compared to medical management, lymphatic embolization generated an incremental cost-effectiveness ratio of US$192,105. Similarly, compared to heart transplantation, lymphatic embolization yielded an incremental cost-effectiveness ratio of US$68,030.

Conclusions:

Of the available plastic bronchitis treatments, with a willingness to pay of US$150,000, lymphatic embolization produces an incremental cost-effectiveness ratio within the bounds considered to be cost-effective, potentially causing financial benefits to the health system.

Keywords

cost–benefit analysis lymphatic embolization Fontan physiology plastic bronchitis

Get full access to this article

View all access options for this article.

References

Mongan

Ferris

Lee

. Options for slowing the growth of health care costs. N Engl J Med. 2008;358(14):1509–1514.

Madsen

Shah

Rubin

. Plastic bronchitis: new insights and a classification scheme. Paediatr Respir Rev. 2005;6(4):292–300.

Rychik

. The relentless effects of the Fontan paradox. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu. 2016;19(1):37–43.

Gossett

Almond

Kirk

. Outcomes of cardiac transplantation in single-ventricle patients with plastic bronchitis: a multicenter study. J Am Coll Cardiol. 2013;61(9):985–986.

Schumacher

Singh

Kuebler

Aprile

O’Brien

Blume

. Risk factors and outcome of Fontan-associated plastic bronchitis: a case-control study. J Am Hear Assoc. 2014;3(2):1–6.

Simpson

Pruitt

Kirklin

. Fontan patient survival after pediatric heart transplantation has improved in the current era. Ann Thorac Surg. 2017;103(4):1315–1320.

Dori

Keller

Fogel

. MRI of lymphatic abnormalities after functional single-ventricle palliation surgery. Am J Roentgenol. 2014;203(2):426–431.

Haseyama

Satomi

Yasukochi

Matsui

Harada

Uchita

. Pulmonary vasodilation therapy with sildenafil citrate in a patient with plastic bronchitis after the Fontan procedure for hypoplastic left heart syndrome. J Thorac Cardiovasc Surg. 2006;132(5):1232–1233.

Dori

Keller

Rome

. Percutaneous lymphatic embolization of abnormal pulmonary lymphatic flow as treatment of plastic bronchitis in patients with congenital heart disease. Circulation. 2016;133(12):1160–1170.

10.

Dori

Keller

Rychik

Itkin

. Successful treatment of plastic bronchitis by selective lymphatic embolization in a Fontan patient. Pediatrics. 2014;134(2):e590–e595.

11.

Avitabile

Goldberg

Dodds

Dori

Ravishankar

Rychik

. A multifaceted approach to the management of plastic bronchitis after cavopulmonary palliation. Ann Thorac Surg. 2014;98(2):634–640.

12.

Mullins

Weisman

. A simplified approach to teaching Markov models. Am J Pharm Educ. 1996;60(1):42–47.

13.

Bonita

Beaglehole

. Recovery of motor function after stroke. Stroke. 1988;19(12):1497–1500.

14.

Rivero Arias

Ouellet

Gray

Wolstenholme

Rothwell

Luengo-Fernandez

. Mapping the modified Rankin scale (mRS) measurement into the generic EuroQol (EQ-5D) health outcome. Med Decis Making. 2010;30(3):341–54.

15.

Owens

. Interpretation of cost-effectiveness analyses. J Gen Intern Med. 1998;13(10):716–717.

16.

Ubel

Hirth

Chernew

Fendrick

. What is the price of life and why doesn’t it increase at the rate of inflation? Arch Intern Med. 2003;163(14):1637–1641.

17.

Gravelle

Smith

. Discounting for health effects in cost–benefit and cost-effectiveness analysis. Healt Econ. 2001;10(7):587–599.

18.

Arias

Heron

. United States Life Tables, 2013. Natl Vital Stat Rep. 2017;66(3):1–64.

19.

Caruthers

Kempa

Loo

. Demographic characteristics and estimated prevalence of Fontan-associated plastic bronchitis. Pediatr Cardiol. 2013;34(2):256–261.

20.

Singhi

Vinoth

Kuruvilla

Sivakumar

. Plastic bronchitis. Ann Pediatr Cardiol. 2015;8(3):246–248.

21.

Onoue

Adachi

Ichida

Miyawaki

. Effective use of corticosteroid in a child with life-threatening plastic bronchitis after Fontan operation. Pediatr Int. 2003;45(1):107–109.

22.

Itkin

McCormack

Dori

. Diagnosis and treatment of lymphatic plastic bronchitis in adults using advanced lymphatic imaging and percutaneous embolization. Ann Am Thorac Soc. 2016;13(10):1689–1696.

23.

Sulemanjee

Merla

Lick

. The first year post-heart transplantation: use of immunosuppressive drugs and early complications. J Cardiovasc Pharmacol Ther. 2008;13(1):13–31.

24.

Cohen

Reynolds

. Interpreting the results of cost-effectiveness studies. J Am Coll Cardiol. 2008;52(25):2119–2126.

25.

Larue

Gossett

Stewart

Backer

Mavroudis

Jacobs

. Plastic bronchitis in patients with Fontan physiology: review of the literature and preliminary experience with Fontan conversion and cardiac transplantation. World J Pediatr Congenit Heart Surg. 2012;3(3):364–372.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.14 MB